Digipath, Inc. (DIGP)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist Digipath, Inc. (DIGP) ein Healthcare-Unternehmen mit einer Bewertung von 0. Bewertet mit 44/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 17. März 2026Digipath, Inc. (DIGP) Gesundheitswesen & Pipeline-Uebersicht
Digipath, Inc. offers specialized cannabis and hemp testing services, ensuring safety and regulatory compliance for Nevada's licensed medical marijuana industry. The company distinguishes itself through comprehensive contaminant screening and educational resources, positioning it as a key player in the cannabis quality assurance sector.
Investmentthese
Digipath, Inc. presents a focused investment opportunity within the niche market of cannabis and hemp testing. The company's revenue is tied to the growth and regulatory requirements of the Nevada cannabis industry. As the industry matures and regulations become more stringent, the demand for reliable testing services is expected to increase. Digipath's established presence in Las Vegas positions it to capitalize on this trend. However, the company's financial performance, indicated by a negative P/E ratio of -1.91 and a small market capitalization, suggests a high-risk investment profile. Growth catalysts include potential expansion into other states and increased service offerings. The primary risk lies in the competitive landscape and the potential for regulatory changes that could impact the demand for testing services.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Digipath, Inc. operates in the cannabis and hemp testing market, providing essential services to ensure product safety and regulatory compliance.
- The company's headquarters are located in Las Vegas, Nevada, positioning it within a key market for the cannabis industry.
- Digipath employs 17 individuals, reflecting its scale of operations within the specialized testing sector.
- The company's negative P/E ratio of -1.91 indicates that it is not currently profitable, suggesting potential challenges in achieving sustained profitability.
- Digipath's beta of 0.42 suggests that its stock price is less volatile than the overall market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Specialized cannabis and hemp testing services.
- Located in the Nevada cannabis market.
- Comprehensive contaminant screening.
- Focus on regulatory compliance.
Schwaechen
- Small market capitalization.
- Negative P/E ratio indicating lack of profitability.
- Limited geographic reach.
- Dependence on the Nevada cannabis market.
Katalysatoren
- Ongoing: Increasing legalization of cannabis in other states, potentially expanding Digipath's market reach.
- Ongoing: Growing demand for cannabis testing services due to stricter regulatory requirements.
- Upcoming: Potential partnerships with cannabis producers and dispensaries to secure testing contracts.
- Upcoming: Development of new testing services to address emerging needs in the cannabis industry.
Risiken
- Potential: Competition from other testing laboratories in the cannabis market.
- Potential: Regulatory changes impacting the cannabis industry and testing requirements.
- Potential: Fluctuations in the demand for cannabis products affecting testing volumes.
- Ongoing: Limited financial disclosure due to OTC Other tier status.
- Ongoing: Lower liquidity and wider bid-ask spreads in the OTC market.
Wachstumschancen
- Expansion into New Geographic Markets: Digipath could expand its testing services to other states with legalized cannabis markets, such as California, Colorado, and Illinois. The US cannabis testing market is projected to reach $2 billion by 2028. Entering new markets would require establishing new laboratory facilities and obtaining necessary licenses, but it could significantly increase Digipath's revenue and market share. This expansion could begin within the next 2-3 years as more states legalize cannabis.
- Development of New Testing Services: Digipath could develop new testing services to address emerging needs in the cannabis industry, such as testing for new contaminants, potency testing for different cannabinoids, and genetic testing of cannabis plants. The market for specialized cannabis testing services is growing rapidly. By offering a wider range of testing options, Digipath could attract new customers and increase revenue from existing clients. This could be implemented within the next 1-2 years.
- Partnerships with Cannabis Producers and Dispensaries: Digipath could form strategic partnerships with cannabis producers and dispensaries to provide on-site testing services or to become their preferred testing provider. These partnerships would provide Digipath with a steady stream of testing samples and increase its brand awareness within the cannabis industry. The timeline for establishing these partnerships is within the next year.
- Offering Educational and Training Programs: Digipath could expand its educational and training programs for cannabis industry professionals, covering topics such as testing methodologies, quality control, and regulatory compliance. The demand for cannabis education is growing as the industry becomes more regulated. By offering valuable training programs, Digipath could establish itself as a thought leader in the cannabis testing space and generate additional revenue. This initiative could be launched within the next 6-12 months.
- Investment in Advanced Testing Technologies: Digipath could invest in advanced testing technologies, such as high-throughput screening and mass spectrometry, to improve the accuracy, speed, and efficiency of its testing services. These technologies would allow Digipath to process a larger volume of samples and provide more detailed testing results. The investment in advanced technologies would enhance Digipath's competitive advantage and attract customers seeking the highest quality testing services. This could be implemented over the next 2-3 years.
Chancen
- Expansion into new geographic markets.
- Development of new testing services.
- Partnerships with cannabis producers and dispensaries.
- Offering educational and training programs.
Risiken
- Competition from other testing laboratories.
- Regulatory changes impacting the cannabis industry.
- Fluctuations in the demand for cannabis products.
- Potential for new contaminants and testing requirements.
Wettbewerbsvorteile
- Specialized expertise in cannabis and hemp testing.
- Established presence in the Nevada cannabis market.
- Comprehensive testing services covering a wide range of contaminants.
- Focus on regulatory compliance and product safety.
Ueber DIGP
Digipath, Inc., established in 2010 and headquartered in Las Vegas, Nevada, operates as a cannabis and hemp testing laboratory. The company serves Nevada's licensed medical marijuana enterprises, offering a suite of testing services designed to ensure product safety and regulatory compliance. Digipath's services include screening for contaminants such as residual solvents, pesticides, heavy metals, and microbial contaminants in cannabis, cannabis-infused products, hemp, and other botanical nutraceuticals. These tests cater to growers, dispensaries, caregivers, producers, patients, and end-users, ensuring that products meet stringent quality standards. Beyond testing, Digipath provides cannabis education and training, along with cannabis news coverage, contributing to industry knowledge and best practices. The company's laboratory facility is equipped to perform a wide array of tests, including moisture analysis, water activity assessments, and visual inspections, ensuring a comprehensive approach to quality control. By focusing on testing and education, Digipath aims to support the growth of a safe and regulated cannabis industry in Nevada.
Was das Unternehmen tut
- Provides cannabis and hemp lab testing services.
- Screens cannabis for contaminants like pesticides and heavy metals.
- Offers testing for residual solvents and microbial contaminants.
- Conducts moisture and water activity analysis.
- Provides cannabis education and training.
- Offers cannabis news coverage.
Geschaeftsmodell
- Generates revenue by charging fees for cannabis and hemp testing services.
- Offers testing services to growers, dispensaries, and producers.
- Provides education and training programs for cannabis industry professionals.
Branchenkontext
Digipath, Inc. operates within the rapidly evolving cannabis industry, specifically in the niche of testing and quality assurance. The cannabis market is experiencing substantial growth, driven by increasing legalization and acceptance of cannabis for medical and recreational use. This growth necessitates robust testing services to ensure product safety and compliance with regulations. The competitive landscape includes other testing laboratories and analytical service providers. Digipath's success depends on its ability to maintain high standards of accuracy, reliability, and customer service in a dynamic regulatory environment.
Wichtige Kunden
- Licensed medical marijuana enterprises in Nevada.
- Cannabis growers.
- Cannabis dispensaries.
- Cannabis producers.
- Caregivers, patients, and end-users of cannabis products.
Finanzdaten
Chart & Info
Digipath, Inc. (DIGP) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Tuesday
· 24. März 2020
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer DIGP.
Kursziele
Wall-Street-Kurszielanalyse fuer DIGP.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von DIGP auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: A. Stone Douglass
CEO
A. Stone Douglass serves as the CEO of Digipath, Inc. While specific details regarding his prior experience and educational background are not provided, his role involves managing the company's operations and strategic direction within the cannabis testing industry. As CEO, Douglass is responsible for overseeing the company's laboratory services, education programs, and news coverage related to the cannabis sector. His leadership is crucial for navigating the evolving regulatory landscape and ensuring Digipath's continued growth and compliance.
Erfolgsbilanz: As CEO of Digipath, A. Stone Douglass is responsible for guiding the company's strategy in the cannabis testing market. With a team of 17 employees, Douglass focuses on providing comprehensive testing services to Nevada's licensed medical marijuana enterprises. His leadership is essential for maintaining the company's position in the competitive cannabis testing industry and ensuring its adherence to regulatory standards. Specific achievements and milestones under his leadership are not detailed in the provided information.
DIGP OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Digipath, Inc. may not meet the minimum financial standards or reporting requirements of the higher OTC tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure, which increases investment risk. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may not be required to file regular financial reports with the SEC, leading to less transparency and information available to investors.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure due to OTC Other tier status.
- Lower liquidity and wider bid-ask spreads compared to major exchanges.
- Potential for price volatility and market manipulation.
- Higher risk of fraud or mismanagement due to less regulatory oversight.
- Dependence on the Nevada cannabis market.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's competitive position in the cannabis testing market.
- Evaluate the company's compliance with regulatory requirements.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Confirm the company's good standing with the Nevada Secretary of State.
- Operation as a cannabis and hemp testing laboratory since 2010.
- Provision of testing services to Nevada's licensed medical marijuana enterprises.
- Focus on regulatory compliance and product safety.
- Presence in the cannabis testing industry.
Haeufige Fragen zu DIGP
What are the key factors to evaluate for DIGP?
Digipath, Inc. (DIGP) currently holds an AI score of 44/100, indicating low score. Key strength: Specialized cannabis and hemp testing services.. Primary risk to monitor: Potential: Competition from other testing laboratories in the cannabis market.. This is not financial advice.
How frequently does DIGP data refresh on this page?
DIGP prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven DIGP's recent stock price performance?
Recent price movement in Digipath, Inc. (DIGP) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized cannabis and hemp testing services.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider DIGP overvalued or undervalued right now?
Determining whether Digipath, Inc. (DIGP) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying DIGP?
Before investing in Digipath, Inc. (DIGP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding DIGP to a portfolio?
Potential reasons to consider Digipath, Inc. (DIGP) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Specialized cannabis and hemp testing services.. Additionally: Located in the Nevada cannabis market.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of DIGP?
Yes, most major brokerages offer fractional shares of Digipath, Inc. (DIGP) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track DIGP's earnings and financial reports?
Digipath, Inc. (DIGP) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for DIGP earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be limited due to the company's OTC listing and disclosure status.
- Financial metrics and analyst opinions may not be readily available for OTC stocks.